{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:16:10Z","timestamp":1789478170959,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570156"],"award-info":[{"award-number":["81570156"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Guangdong Provincial Basic Research Program, PR China","award":["2015B020227003"],"award-info":[{"award-number":["2015B020227003"]}]},{"name":"Science and Technology Program of Guangzhou, PR China","award":["201607010072"],"award-info":[{"award-number":["201607010072"]}]},{"name":"Medical Innovation Program of Fujian Province, PR China","award":["2016-CXB-7"],"award-info":[{"award-number":["2016-CXB-7"]}]},{"name":"Guangdong Provincial Applied Science and Technology Research Development Program","award":["2016B020237006"],"award-info":[{"award-number":["2016B020237006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13148-017-0377-8","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T07:37:04Z","timestamp":1502696224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells"],"prefix":"10.1186","volume":"9","author":[{"given":"Yin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leisi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manman","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suqi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,14]]},"reference":[{"issue":"8","key":"377_CR1","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1158\/1535-7163.MCT-09-0138","volume":"8","author":"MC Crisanti","year":"2009","unstructured":"Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 2009;8(8):2221\u201331. doi:\n10.1158\/1535-7163.MCT-09-0138\n\n.","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"377_CR2","doi-asserted-by":"publisher","first-page":"8403","DOI":"10.1158\/0008-5472.CAN-09-2146","volume":"69","author":"X Huang","year":"2009","unstructured":"Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res. 2009;69(21):8403\u201311. doi:\n10.1158\/0008-5472.CAN-09-2146\n\n.","journal-title":"Cancer Res"},{"issue":"1","key":"377_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12185-015-1897-7","volume":"103","author":"Y Ogawa","year":"2016","unstructured":"Ogawa Y, Ogura M, Tobinai K, Ando K, Suzuki T, Watanabe T, et al. A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Int J Hematol. 2016;103(1):25\u201333. doi:\n10.1007\/s12185-015-1897-7\n\n.","journal-title":"Int J Hematol"},{"issue":"1","key":"377_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","volume":"109","author":"M Duvic","year":"2007","unstructured":"Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous t-cell lymphoma (CTCL). Blood. 2007;109(1):31\u20139. doi:\n10.1182\/blood-2006-06-025999\n\n.","journal-title":"Blood"},{"issue":"11","key":"377_CR5","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.7150\/thno.16139","volume":"6","author":"Y Jin","year":"2016","unstructured":"Jin Y, Yao Y, Chen L, Zhu X, Jin B, Shen Y, et al. Depletion of \u03b3-catenin by histone deacetylase inhibition confers elimination of CML stem cells in combination with imatinib. Theranostics. 2016;6(11):1947\u201362. doi:\n10.7150\/thno.16139\n\n.","journal-title":"Theranostics"},{"issue":"6","key":"377_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00428-006-0173-x","volume":"448","author":"P Piacentini","year":"2006","unstructured":"Piacentini P, Donadelli M, Costanzo C, Moore PS, Palmieri M, Scarpa A. Trichostatin a enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch. 2006;448(6):797\u2013804. doi:\n10.1007\/s00428-006-0173-x\n\n.","journal-title":"Virchows Arch"},{"issue":"2","key":"377_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.bbrc.2010.01.011","volume":"392","author":"L Liu","year":"2010","unstructured":"Liu L, Chen B, Qin S, Li S, He X, Qiu S, et al. A novel histone deacetylase inhibitor chidamide induces apoptosis of human colon cancer cells. Biochem Biophys Res Commun. 2010;392(2):190\u20135. doi:\n10.1016\/j.bbrc.2010.01.011\n\n.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"377_CR8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00280-012-1847-5","volume":"69","author":"M Dong","year":"2012","unstructured":"Dong M, Ning ZQ, Xing PY, Xu JL, Cao HX, Dou GF, et al. Phase I study of chidamide (CS055\/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol. 2012;69(6):1413\u201322. doi:\n10.1007\/s00280-012-1847-5\n\n.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"377_CR9","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral t-cell lymphoma. Ann Oncol. 2015;26(8):1766\u201371. doi:\n10.1093\/annonc\/mdv237\n\n.","journal-title":"Ann Oncol"},{"issue":"6","key":"377_CR10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2174\/156800961506150805153230","volume":"15","author":"Y Li","year":"2015","unstructured":"Li Y, Chen K, Zhou Y, Xiao Y, Deng M, Jiang Z, et al. A new strategy to target acute myeloid leukemia stem and progenitor cells using chidamide, a histone deacetylase inhibitor. Curr Cancer Drug Targets. 2015;15(6):493\u2013503.","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"377_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bbrc.2013.03.059","volume":"434","author":"Z Qiao","year":"2013","unstructured":"Qiao Z, Ren S, Li W, Wang X, He M, Guo Y, et al. Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells. Biochem Biophys Res Commun. 2013;434(1):95\u2013101. doi:\n10.1016\/j.bbrc.2013.03.059\n\n.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"377_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.biopha.2014.03.011","volume":"68","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Pan DS, Shan S, Zhu JZ, Zhang K, Yue X, et al. Non-toxic dose chidamide synergistically enhances platinum-induced dna damage responses and apoptosis in non-small-cell lung cancer cells. Biomed Pharmacother. 2014;68(4):483\u201391. doi:\n10.1016\/j.biopha.2014.03.011\n\n.","journal-title":"Biomed Pharmacother"},{"issue":"18","key":"377_CR13","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1182\/blood-2016-11-751008","volume":"129","author":"R Lal","year":"2017","unstructured":"Lal R, Lind K, Heitzer E, Ulz P, Aubell K, Kashofer K, et al. Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. Blood. 2017;129(18):2587\u201391. doi:\n10.1182\/blood-2016-11-751008\n\n.","journal-title":"Blood"},{"key":"377_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/B978-0-12-394387-3.00006-9","volume":"116","author":"S Grant","year":"2012","unstructured":"Grant S, Dai Y. Histone deacetylase inhibitors and rational combination therapies. Adv Cancer Res. 2012;116:199\u2013237. doi:\n10.1016\/B978-0-12-394387-3.00006-9\n\n.","journal-title":"Adv Cancer Res"},{"issue":"12","key":"377_CR15","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352. doi:\n10.1056\/NEJMra1406184\n\n.","journal-title":"N Engl J Med"},{"issue":"3","key":"377_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4331\/wjbc.v6.i3.57","volume":"6","author":"QE Wang","year":"2015","unstructured":"Wang QE. DNA damage responses in cancer stem cells: implications for cancer therapeutic strategies. World J Biol Chem. 2015;6(3):57\u201364. doi:\n10.4331\/wjbc.v6.i3.57\n\n.","journal-title":"World J Biol Chem"},{"issue":"3","key":"377_CR17","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.radonc.2013.10.040","volume":"110","author":"A Desai","year":"2014","unstructured":"Desai A, Webb B, Gerson SL. CD133+ cells contribute to radioresistance via altered regulation of dna repair genes in human lung cancer cells. Radiother Oncol. 2014;110(3):538\u201345. doi:\n10.1016\/j.radonc.2013.10.040\n\n.","journal-title":"Radiother Oncol"},{"issue":"12","key":"377_CR18","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1158\/0008-5472.CAN-07-6353","volume":"68","author":"M Zhang","year":"2008","unstructured":"Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008;68(12):4674\u201382. doi:\n10.1158\/0008-5472.CAN-07-6353\n\n.","journal-title":"Cancer Res"},{"issue":"5","key":"377_CR19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/MPA.0b013e31821ae25b","volume":"40","author":"LA Mathews","year":"2011","unstructured":"Mathews LA, Cabarcas SM, Hurt EM, Zhang X, Jaffee EM, Farrar WL. Increased expression of dna repair genes in invasive human pancreatic cancer cells. Pancreas. 2011;40(5):730\u20139. doi:\n10.1097\/MPA.0b013e31821ae25b\n\n.","journal-title":"Pancreas"},{"issue":"7120","key":"377_CR20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756\u201360. doi:\n10.1038\/nature05236\n\n.","journal-title":"Nature"},{"issue":"10","key":"377_CR21","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1158\/1535-7163.MCT-08-0385","volume":"7","author":"RR Rosato","year":"2008","unstructured":"Rosato RR, Almenara JA, Maggio SC, Coe S, Atadja P, Dent P, et al. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824\/fludarabine antileukemic interactions. Mol Cancer Ther. 2008;7(10):3285\u201397. doi:\n10.1158\/1535-7163.MCT-08-0385\n\n.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"377_CR22","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1038\/leu.2009.182","volume":"23","author":"P Maiso","year":"2009","unstructured":"Maiso P, Colado E, Ocio EM, Garayoa M, Martin J, Atadja P, et al. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for hdac inhibitors in the control of dna repair. Leukemia. 2009;23(12):2265\u201374. doi:\n10.1038\/leu.2009.182\n\n.","journal-title":"Leukemia"},{"issue":"10","key":"377_CR23","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1158\/0008-5472.CAN-15-2680","volume":"76","author":"A Krumm","year":"2016","unstructured":"Krumm A, Barckhausen C, Kucuk P, Tomaszowski KH, Loquai C, Fahrer J, et al. Enhanced histone deacetylase activity in malignant melanoma provokes RAD51 and FANCD2-triggered drug resistance. Cancer Res. 2016;76(10):3067\u201377. doi:\n10.1158\/0008-5472.CAN-15-2680\n\n.","journal-title":"Cancer Res"},{"issue":"6","key":"377_CR24","doi-asserted-by":"publisher","first-page":"e11208","DOI":"10.1371\/journal.pone.0011208","volume":"5","author":"SK Kachhap","year":"2010","unstructured":"Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MS, Wissing MD, Hedayati M, et al. Downregulation of homologous recombination DNA repair genes by hdac inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One. 2010;5(6):e11208. doi:\n10.1371\/journal.pone.0011208\n\n.","journal-title":"PLoS One"},{"issue":"11","key":"377_CR25","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.1158\/0008-5472.CAN-06-3996","volume":"67","author":"CS Chen","year":"2007","unstructured":"Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, et al. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res. 2007;67(11):5318\u201327. doi:\n10.1158\/0008-5472.CAN-06-3996\n\n.","journal-title":"Cancer Res"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-017-0377-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T07:37:11Z","timestamp":1502696231000},"score":1,"resource":{"primary":{"URL":"http:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-017-0377-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,14]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["377"],"URL":"https:\/\/doi.org\/10.1186\/s13148-017-0377-8","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,14]]},"article-number":"83"}}